Business Wire

AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today hosted a panel of ...
Business Insider

Spur Therapeutics to Present New Clinical Data on Its Gene Therapy Candidate in Gaucher Disease at Upcoming ESGCT Annual Congress

LONDON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced it will present new clinical data for avigbagene parvec (FLT201), its Phase 3-ready gene therapy candidate for Gaucher ...
Nasdaq

Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022 “The FDA clearance of this IND is an important milestone for FLT201, which is the first ...
WNCT

Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease

On track to dose first patient in Phase 3 trial in second half of 2025 LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced positive feedback from its end-of-Phase 2 (EOP2) ...
WOOD-TV

Oral and poster presentations highlight FLT201’s potential to set a new standard of care

LONDON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced data from its Phase 1/2 GALILEO-1 trial of FLT201, an adeno-associated virus (AAV) gene therapy candidate for Gaucher ...
Business Wire

AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy

New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02 Data from first pediatric GD3 ...
KRON4 News

Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium™

LONDON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced data from its Phase 1/2 GALILEO-1 trial of FLT201, an adeno-associated virus (AAV) gene therapy candidate for Gaucher ...
The Forward

This Jewish disease wreaks havoc. But it may have an upside.

A rare genetic disorder that disproportionately affects Ashkenazi Jews is also a safeguard against tuberculosis, a new study shows, and that discovery could explain a longstanding scientific mystery.
WTNH

Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease

FLT201 is a highly differentiated AAV gene therapy candidate that delivers a longer-acting engineered variant of GCase, the enzyme missing in people with Gaucher disease Company expects to report ...
WFLA News Channel 8

Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that FLT201 has been awarded the Innovation Passport for the treatment of Gaucher disease ...